Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

Published:2017-04-24 Issue:11 Volume:64 Page:e26563
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Mody Rajen¹,Zhao Lili²,Yanik Gregory Anthony¹,Opipari Valerie¹³

Affiliation:

1. Department of Pediatrics and Communicable Diseases; University of Michigan; Ann Arbor Michigan

2. Department of Biostatistics; University of Michigan; Ann Arbor Michigan

3. A. Alfred Taubman Research Institute; University of Michigan; Ann Arbor Michigan

Funder

University of Michigan Comprehensive Cancer Center

Clinical and Translational Research Award

Investigator Initiated Clinical Grant

Millennium Pharmaceutical Inc.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference45 articles.

1. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial;Kreissman;Lancet Oncol,2013

2. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study;Matthay;J Clin Oncol,2009

3. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial;Pearson;Lancet Oncol,2008

4. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study;Bagatell;J Clin Oncol,2011

5. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials;Moreno;Pediatr Blood Cancer,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear factor-κB activation by transforming growth factor-β1 drives tumour microenvironment-mediated drug resistance in neuroblastoma;British Journal of Cancer;2024-05-28

2. Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment;Scientific Reports;2024-02-14

3. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects;JCO Precision Oncology;2024-02

4. Part II: Adaptive designs in pediatric clinical trials: specific examples, comparison with adult trials and a discussion for the child health community;2024-01-10

5. Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations;International Journal of Molecular Sciences;2022-09-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3